Navigation Links
GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/14/2008

ver

50% of the AIDS virus (HIV-1) protein components in order to stimulate

a broad anti-HIV immune response. The vaccines cannot cause AIDS

because they do not include complete virus. A Phase 1 human trial,

started in April 2006, evaluated the delivery of only 1/10th of the

full dosage and utilized the same vaccine regimen evaluated in the full

dose trial.

From data collected from the 26 participants who completed the trial, the following positive conclusions were observed:
-- GeoVax HIV/AIDS vaccines, both DNA and MVA, continue to demonstrate

that they are quite safe and immunogenic following the delivery of

the four full-doses (two of each vaccine) used in the trial's

protocol.

-- The full-dose regimen of GeoVax vaccines continues to be well

tolerated without any type of reaction, mild or systemic, in the

majority of participants.

-- CD4 T-cell responses are high in both the low and full-dose regimens,

84% and 78% of participants.

-- CD8 T-cell responses are present in 42% of the full-dose recipients

and 33% of the 1/10th dose recipients.

-- Antibody responses to the envelope glycoprotein (Env) increased

following the fourth vaccination, and were present in 88% of the

full-dose participants.

-- Delivery of the fourth vaccination increased the frequency and

magnitude of the CD8 T-cell and Antibody responses.

-- During November 2007 through January 2008, GeoVax raised approximately

$3 million in equity capital through a series of privately negotiated

transactions with individual accredited investors and one institutional

investor. These funds, along with the funds received pursuant to the

NIH grant discussed above will be used to offset the Company's ongoing

research and development costs and
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
2. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
3. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
4. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
5. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
6. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
7. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
10. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
11. PLC Systems Reports Fourth Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Inc. ( www.synapsebiomedical.com ) announced today it has ... its NeuRx DPS® System for ALS patients.  The ... requirement was implanted over a month and a ... is the only medical device approved by the ... device that obtained approval at the end of ...
(Date:9/30/2014)... Netherlands , Sept. 30, 2014  eHealth, ... phone storage and access of this information, has ... Slot , however, that has not translated into ... http://photos.prnewswire.com/prnh/20140929/149122 Photo - http://photos.prnewswire.com/prnh/20140929/149123 ... the past few years developing MWD® Health Manager ...
(Date:9/30/2014)... 30, 2014 It is evident from the industry ... not performing upto expectations due to the lack of promotional ... the intake of omega-3 fatty acids. Among omega-3 ingredient sources ... oil, attributed to the large vegetarian population in ... fatty acid (PUFAs) ingredients is in growth stage of its ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3MWD Challenges the Big eHealth Players With New Software for Your Smartphone 2Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2
... FRANCISCO, Oct. 29 Medivation, Inc. (Nasdaq: MDVN ... webcast with management to discuss third quarter 2010 financial results ... at 4:30 p.m. Eastern Time. A press release for the ... markets close on November 5, 2010. Interested ...
... N.Y., Oct. 29 Henry Schein, Inc. (Nasdaq: ... to office-based practitioners, today reported record financial results for the ... the third quarter of 2010 were $1.9 billion, an increase ... consists of 16.4% growth in local currencies and a decline ...
Cached Medicine Technology:Henry Schein Reports Record Third Quarter Results 2Henry Schein Reports Record Third Quarter Results 3Henry Schein Reports Record Third Quarter Results 4Henry Schein Reports Record Third Quarter Results 5Henry Schein Reports Record Third Quarter Results 6Henry Schein Reports Record Third Quarter Results 7Henry Schein Reports Record Third Quarter Results 8Henry Schein Reports Record Third Quarter Results 9Henry Schein Reports Record Third Quarter Results 10Henry Schein Reports Record Third Quarter Results 11
(Date:9/30/2014)... Austin, TX (PRWEB) September 30, 2014 ... for Facial Plastic Surgery, has been approved to be ... of Facial Plastic and Reconstructive Surgery (AAFPRS) fellowship program. ... their meeting in Orlando, Florida. , The Educational and ... throughout the medical community. It represents the finest postgraduate ...
(Date:9/30/2014)... 30, 2014 Neuromuscular and central ... the United States and worldwide. It is estimated ... diagnosed each year, adding to the more than ... Approximately 400,000 people in the US are affected ... to these statistics the 2.4 percent of the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... caring individuals, National Children’s Oral Health Foundation: ... in grants to non-profit clinical partners. These ... Network and deliver comprehensive educational, preventive and ... Recipients include:,     Just Kids ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Pivotal 5, ... solutions, today announced Life Time – The Healthy Way ... destination for KettleWorX Group Training . KettleWorX Group ... fitness facilities. KettleWorX offers consumers of all fitness levels ... fun and effective manner. The rollout to Life Time ...
(Date:9/30/2014)... 2014 (HealthDay News) -- Herceptin is the best drug ... and should remain the standard of care for that ... long-term clinical trial. HER2-positive breast cancers tend to ... according to the Mayo Clinic. For the study, ... Herceptin (trastuzumab) or Tykerb (lapatinib) in addition to standard ...
Breaking Medicine News(10 mins):Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 2Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3Health News:Pivotal 5 Announces Life Time Fitness As National Destination For KettleWorX Kettlebell Training 2Health News:Pivotal 5 Announces Life Time Fitness As National Destination For KettleWorX Kettlebell Training 3
... blood pressure is well known, however// a new study reports ... published today in the Open Access journal Environmental Health for ... of salt particles can have just the same effect on ... an occupational health hazard for workers in salt factory. It ...
... Authority (NPPA) has been working// on bringing down the ... the manufacturers and has finally succeeded. According to NPPA ... bring about a price reduction ranging between 2.14% to ... hearing to explain the reasons for steep price increase ...
... Gengraine Technologies (Avesthagen) of India is collaborating// with ... Developing Countries (IFU) of Germany for Osteoporosis research. ... euro. Avesthagen said “"The alliance will cover diagnosis, ... disorders.” The research studies related to menopause linked ...
... patients with diastolic heart failure increases// the survival rate ... ,William C. Little and his research team from ... heart failure (DHF) treated with statins has better survival ... failure patients published in the Journal Circulation: Journal of ...
... For the elderly population, adjusting to the raising temperatures// in ... heat that may affect the elderly people are heat exhaustion ... Health Letter from the Harvard Medical School had given some ... a little easier during the summers. ,In addition to ...
... article reviewing the research carried out so far into the ... revealed that a new phase III trial is scheduled to ... CoQ10 has escalated, causing soaring prices and reports of fake ... to have been triggered by the publication of Shults’ earlier ...
Cached Medicine News:Health News:Hypertension can be caused by Inhalation of Salt 2Health News:Hypertension can be caused by Inhalation of Salt 3Health News:Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients 2Health News:Elderly People Needs To Tackle The Heat Effectively 2Health News:New Study to look at the Beneficial Effects of Coenzyme Q10 on Parkinson’s disease 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: